Commerzbank Aktiengesellschaft FI Grows Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Commerzbank Aktiengesellschaft FI increased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 4.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 10,463 shares of the biopharmaceutical company’s stock after buying an additional 464 shares during the quarter. Commerzbank Aktiengesellschaft FI’s holdings in Gilead Sciences were worth $963,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in GILD. Swedbank AB grew its stake in shares of Gilead Sciences by 10.2% in the third quarter. Swedbank AB now owns 2,047,609 shares of the biopharmaceutical company’s stock valued at $171,672,000 after buying an additional 189,622 shares in the last quarter. Chicago Partners Investment Group LLC grew its stake in shares of Gilead Sciences by 8.6% in the third quarter. Chicago Partners Investment Group LLC now owns 6,850 shares of the biopharmaceutical company’s stock valued at $598,000 after buying an additional 540 shares in the last quarter. Harbor Capital Advisors Inc. grew its stake in shares of Gilead Sciences by 2.6% in the third quarter. Harbor Capital Advisors Inc. now owns 27,005 shares of the biopharmaceutical company’s stock valued at $2,264,000 after buying an additional 695 shares in the last quarter. PDS Planning Inc grew its stake in shares of Gilead Sciences by 10.6% in the third quarter. PDS Planning Inc now owns 4,500 shares of the biopharmaceutical company’s stock valued at $377,000 after buying an additional 433 shares in the last quarter. Finally, Moloney Securities Asset Management LLC grew its stake in shares of Gilead Sciences by 5.4% in the third quarter. Moloney Securities Asset Management LLC now owns 25,975 shares of the biopharmaceutical company’s stock valued at $2,178,000 after buying an additional 1,326 shares in the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the company. Daiwa America upgraded Gilead Sciences to a “hold” rating in a research note on Monday, November 18th. Mizuho increased their price target on Gilead Sciences from $90.00 to $100.00 and gave the company an “outperform” rating in a report on Thursday, November 21st. Wells Fargo & Company increased their price target on Gilead Sciences from $105.00 to $120.00 and gave the company an “overweight” rating in a report on Wednesday, February 12th. Barclays increased their price target on Gilead Sciences from $84.00 to $95.00 and gave the company an “equal weight” rating in a report on Thursday, November 7th. Finally, Maxim Group downgraded Gilead Sciences from a “buy” rating to a “hold” rating in a report on Friday, November 8th. Eleven analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $102.76.

Insider Buying and Selling

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total value of $228,375.00. Following the completion of the transaction, the chief financial officer now directly owns 129,873 shares of the company’s stock, valued at approximately $11,863,898.55. The trade was a 1.89 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold a total of 293,356 shares of company stock valued at $29,166,240 over the last three months. Company insiders own 0.16% of the company’s stock.

Gilead Sciences Trading Down 1.1 %

GILD stock opened at $114.74 on Wednesday. The company has a market cap of $143.00 billion, a P/E ratio of 310.11, a PEG ratio of 0.71 and a beta of 0.21. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $117.39. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. The business has a fifty day moving average of $98.28 and a 200-day moving average of $90.74.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, topping analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. As a group, equities research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be paid a dividend of $0.79 per share. The ex-dividend date is Friday, March 14th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.75%. Gilead Sciences’s payout ratio is 854.05%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.